Previous 10 | Next 10 |
2024-03-11 16:52:03 ET More on AnaptysBio Stifel starts AnaptysBio at buy, cites upcoming catalysts AnaptysBio gains as Piper Sandler starts at Overweight on catalyst path Seeking Alpha’s Quant Rating on AnaptysBio Historical earnings data for AnaptysB...
Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist, with top-line data anticipated by year-end 2024 Enrollment ongoing for global Phase 2b trial to treat rheumatoid arthritis (RA) and global Phase 2 trial to treat ulcerative colitis (UC)...
2024-03-10 13:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Klepierre (KLPEF) is expected to report for Q4 2023 comScore Inc. (SCOR) is expected to report $0.8 for Q4 2023 Universal Stainless & Alloy Products Inc. (USAP) is expected to report for Q4 2023 FAT Brands Inc. (FAT) is expected to report $-1.55 for Q4 2023 Jet.AI Inc. (JTAI) ...
SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer, will participate in a panel discussion at TD Cowe...
2024-02-21 14:16:21 ET More on AnaptysBio AnaptysBio gains as Piper Sandler starts at Overweight on catalyst path Seeking Alpha’s Quant Rating on AnaptysBio Historical earnings data for AnaptysBio Financial information for AnaptysBio Read the...
2024-02-16 12:21:21 ET More on AnaptysBio Seeking Alpha’s Quant Rating on AnaptysBio Historical earnings data for AnaptysBio Financial information for AnaptysBio Read the full article on Seeking Alpha For further details see: AnaptysBio gai...
SAN DIEGO, Jan. 31, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer, will present at Guggenheim’s 6 th Annu...
2024-01-06 02:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Anaptys licenses exclusive global development and commercialization rights to a potential best-in-class BDCA2 modulator portfolio IND filing to support clinical development of ANB101 in autoimmune and inflammatory diseases expected in H2 2024 Reiterating year-end 2023 cash and investmen...
News, Short Squeeze, Breakout and More Instantly...
2024-05-10 18:15:02 ET Wells Fargo analyst issues BUY recommendation for ANAB on May 10, 2024 05:01PM ET. The previous analyst recommendation was Buy. ANAB was trading at $23.41 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current ana...
Anaptys to receive $50 million upfront cash payment from Sagard Healthcare Prior agreement amended to now expire once Sagard receives a capped pa...
Cytek Biosciences, Inc. (NASDAQ: CTKB) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.05. Th...